2024
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian follow-upMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of HealthComparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretion
2022
342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth
GALDERISI A, LAT J, SAMUELS S, PIERPONT B, VAN NAME M, SANTORO N, CAPRIO S. 342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth. Diabetes 2022, 71 DOI: 10.2337/db22-342-or.Peer-Reviewed Original ResearchBeta-cell functionIncretin effectInsulin sensitivityInsulin secretionCell functionFirst-phase insulin secretionIsoglycemic intravenous glucose infusionLongitudinal declineReduced β-cell functionEarly insulin secretionLower insulin sensitivityIntravenous glucose infusionΒ-cell functionOral minimal modelIncretin groupsObese youthGlucose infusionRelative increaseNational InstituteTertileLongitudinal trajectoriesObesitySecretionGlucoseGroup